FDA greenlights freeze-dried mpox, smallpox vaccine

The U.S. Food and Drug Administration has approved the use of a freeze-dried formulation of the Jynneos mpox and smallpox vaccine among patients aged 18 years and older.

The World Health Organization recently declared the mpox public health emergency ongoing, according to a news report from Reuters. Over the past year, there have been over 25,000 incidences of mpox and 70 deaths from the disease.

The FDA’s approval followed positive findings from a clinical trial demonstrating the freeze-dried formulation’s comparable immunogenicity and safety to the previously approved liquid-frozen formulation. The novel formulation is designed to improve the vaccine’s transportation, storage and shelf life — thereby allowing the United States to stockpile the drug over longer periods of time.

Read more: Reuters

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.